A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia

NCT02016755 ↗

Phase 2 Completed 10 enrolled AnGes USA, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to confirm the feasibility of study procedures and the tolerability of a new dose regimen of AMG0001 in subjects with Critical Limb Ischemia (CLI)

Timeline

Start: 2013-11
Primary completion: 2018-03-31
Completion: 2018-03-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HGF Plasmid	Unknown	—	Intramuscular

A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia

Summary

Timeline

Drugs

Indications